Samira Humaira Habib

Diabetic Association of Bangladesh, Mujib City, Dhaka, Bangladesh

Are you Samira Humaira Habib?

Claim your profile

Publications (15)7.69 Total impact

  • 11/2015; 3(1). DOI:10.18035/emj.v3i1.334
  • International Journal of Diabetes in Developing Countries 08/2015; DOI:10.1007/s13410-015-0434-9 · 0.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionThe purpose of this study was to examine the safety and feasibility of laparoscopically assisted vaginal hysterectomy for uteri weighing more than 500 g as compared to uteri weighing less than 500 g in benign gynecological diseases.Methods This was a retrospective study. Patients were admitted through the outpatient department. They were divided into two groups: uterine weight ≥500 g (group 1) and uterine weight >500 g (group 2). There were no exclusion criteria based on the size, number, or location of leiomyomas. The patient characteristics for the two groups were compared in terms of demographic and socioeconomic details, operating time, amount of blood loss, requirement of blood transfusion, need for analgesia, and length of hospital stay.ResultsThe characteristics age and BMI were well balanced between the two groups. Uterine weight was 267.2 ± 97.6 g in group 1 and 740.0 ± 371.4 g in group 2 (P < 0.001). Length of operation and amount of blood loss were greater in group 2 than in group 1 (operation: 89.1 ± 26.7 vs 73.3 ± 24.6 min, P < 0.01; blood loss: 570.5 ± 503.6 vs 262.5 ± 270.0 mL, P < 0.001). However, there was no significant difference in hospital stay or incidence of operative complications between the two groups. No patients were switched from laparoscopy to laparotomy during operation. The rate of blood transfusion was lower in group1 than in group 2 (4.9% vs 32.6%; P < 0.001).Conclusion This study demonstrated that despite the increased operating time and blood loss, laparoscopy should be considered instead of laparotomy in cases of large uteri. Laparoscopically assisted vaginal hysterectomy can be performed safely for a large uterus.
    Asian Journal of Endoscopic Surgery 04/2015; 8(3). DOI:10.1111/ases.12184
  • OALib Journal 01/2014; 01(04):1-7. DOI:10.4236/oalib.1100645
  • 05/2013; 1(2):39-42. DOI:10.11593/bje.2013.0102.0016
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims/Introduction The aim of the present study was to evaluate the predictive ability of body mass index (BMI), waist circumference (WC), waist‐to‐hip ratio (WHR), waist‐to‐height ratio (WHtR) and body fat percentages (BF%) for the presence of cardiometabolic risk factors, namely type 2 diabetes (DM), hypertension (HTN), dyslipidemia and metabolic syndrome (MS). Materials and Methods A total of 2293 subjects aged ≥20 years from rural Bangladesh were randomly selected in a population‐based, cross‐sectional survey. The association of anthropometric indicators with cardiometabolic risk conditions was assessed by using receiver operating characteristic curve analysis and adjusted odds ratios (ORs) for DM, HTN, dyslipidemia and MS. Results Area under the curve cut‐off values showed that the association of WHR, BF% and WC was higher than that for other indices for DM, HTN and MS, respectively, for both sexes, and WHtR for men and WHR for women for dyslipidemia. The ORs were highest for WHR for DM and WC for MS for both sexes, and WHtR for men and WC for women for HTN and dyslipidemia, respectively. The optimal cut‐off values for obesity for the present study in men and women showed BMIs of 22 and 22.8 kg/m2, WHRs of 0.93 and 0.87, WHtRs of 0.52 and 0.54, BF% of 21.4 and 32.4%, and WCs of 82 and 81 cm, except for MS, which were 90 for men and 80 for women. Conclusions Compared with BMI, measures of central obesity, particularly WHR, WC, WHtR and BF%, showed a better association with obesity‐related cardiometabolic risk factors for both sexes.
    Journal of Diabetes Investigstion 12/2012; 4(4). DOI:10.1111/jdi.12053, · 1.83 Impact Factor
  • 12/2012; 2(2). DOI:10.3329/jemc.v2i2.12841
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The aim of the present study was to estimate the incidence of diabetic retinopathy (DR) among type 2 diabetic (T2D) subjects in Bangladesh. Methods: A random sample of 977 patients with T2D was recruited retrospectively in 2008 from newly diagnosed T2D patients who had attended the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorder (BIRDEM) in 1993. Baseline information for the cohort was collected for 1993 from hospital records. The mean time until development of DR in newly diagnosed T2D patients was calculated using survival analysis. Cox’s proportional hazards model was used to assess factors affecting the time until development of DR. Results: The cumulative incidence of DR over the 15-year period was 50.6% (95% confidence interval [CI] 47.5%–53.8%). The incidence density (per 100 person-years) of DR was similar in the overall cohort (4.1; 95% CI 3.7–4.5) and in men (4.2; 95% CI 3.7–4.7) and women (4.1; 95% CI 3.6–4.6) separately. The mean time (in years) until development of DR in the cohort was 9.72 (95% CI 9.38–10.06), with similar times in men (9.8; 95% CI 9.3–10.3) and women (9.6; 95% CI 9.5–10.1) analyzed separately. Age, sex, hypertension, lipid profile, HbA1c, and serum creatinine were entered into the hazards model simultaneously. However, only age (hazard ratio [HR] 0.75; 95% CI 0.61–0.92) and HbA1c (HR 0.52; 95% CI 0.33–0.82) had a significant effect on the time until development of DR. Conclusions: Glucose deregulation is the most important factor in the development of DR.
    Journal of Diabetes 05/2012; 4(4). DOI:10.1111/j.1753-0407.2012.00208.x · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study was undertaken to compare the efficiency and outcome of Laparoscopic Assisted Vaginal Hysterectomy (LAVH) and Vaginal Hysterectomy (VH) in terms of operative time, cost, estimated blood loss, hospital stay, quantity of analgesia use, intra- and postoperative complication rates and patients recovery. A total of 500 diabetic patients were prospectively collected in the study period from January 2005 through January 2009. The performance of LAVH was compared with that of VH, in a tertiary care hospital. The procedures were performed by the same surgeon. There was no significant difference in terms of age, parity, body weight or uterine weight. The mean estimated blood loss in LAVH was significantly lower when compared with the VH group (126.5±39.8 ml and 100±32.8 ml), respectively. As to postoperative pain, less diclofenac was required in the LAVH group compared to the VH group (70.38±13.45 mg and 75.18±16.45 mg), respectively. LAVH, is clinically and economically comparable to VH, with patient benefits of less estimated blood loss, lower quantity of analgesia use, lower rate of intra- and postoperative complications, less postoperative pain, rapid patient recovery, and shorter hospital stay.
    Journal of Obstetrics and Gynaecology 04/2011; 31(3):254-7. DOI:10.3109/01443615.2010.550346 · 0.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leptin is now known to be an important hormone affecting intrauterine fetal growth. Since growth of fetus is also affected by the glycemic status of the mother. Serum leptin of infant is influenced by the maternal diabetic state. Investigation of cord blood leptin in babies of DM (Diabetes Mellitus) and GDM (Gestational Diabetes Mellitus) mothers (controlled blood glucose levels) may provide some indication about involvement of genetic factor in the development of leptin abnormalities in fetus. The study was taken to investigate whether cord blood insulin, c-peptide and leptin levels correlate with birth weight in offspring of DM mother. Blood was drawn from umbilical cord of 30 babies from GDM mothers (GDM-babies), 45 babies from Type 2 DM Mothers (DM-babies), and 30 babies from ND (Nondiabetic) mothers (ND-babies) of term pregnancy. Weight, blood glucose, placenta, serum leptin and c-peptide of the babies were measured. Birth weight of GDM and DM babies were significantly higher compared to ND-babies. Glucose level in GDM babies was significantly higher than ND and DM babies. Leptin levels in GDM babies were significantly higher than that of ND and DM babies. Serum c-peptide in GDM babies was significantly higher than DM and ND babies. However, there was no significant difference in leptin-glucose ratio among the three groups. Irrespective of degree of hyperglycemia leptin is a major determinant of fetal growth. DM mother produces different insulinemic and leptinemic responses in the fetus indicating a possible genetic involvement.
    01/2011; 5(1):33-7. DOI:10.1016/j.dsx.2010.10.001
  • Samira Humaira Habib · Soma Saha
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-communicable diseases continue to be important public health problems in the world, being responsible for sizeable mortality and morbidity. Non-communicable diseases (NCDs) are the leading causes of death and disability worldwide. In 2005 NCDs caused an estimated 35 million deaths, 60% of all deaths globally, with 80% in low income and middle-income countries and approximately 16 million deaths in people less than 70 years of age. Total deaths from NCDs are projected to increases by a further 17% over the next 10 years. Knowing the risk factors for chronic disease means that approximately 80% premature heart disease and stroke, 80% of Type 2 diabetes and 40% of cancers are preventable. Within next 20 years, NCDs will be responsible for virtually half of the global burden of disease in the developing countries. Risk factors, such as tobacco and alcohol use, improper nutrition and sedentary behavior contribute substantially to the development of NCDs, which are sweeping the entire globe, with an increasing trend mostly in developing countries where, the transition imposes more constraints to deal with an increasing burden of over population with existing communicable diseases overwhelmed with increasing NCDs in poorly maintained sanitation and environment.By 2020, it is predicted that these diseases will be causing seven out of every 10 deaths in developing countries. A major feature of the developmental transition is the rapid urbanization and the large shifts in population from rural to urban areas. Even the rural people are increasingly adapting urbanized lifestyle. The changing pattern of lifestyle leads to the development of obesity, stroke, stress, atherosclerosis, cancer and other NCDs.Considering the future burden of NCDs and our existing health care system we should emphasize the need to prioritize the prevention and control of NCDs. Our strategies should be directed to monitor the incidence of NCDs along with their risk factors. Some NCDs have their common risk factors which should be addressed with minimum cost but maximum output. The three key components of the strategy are surveillance, health promotion and primary prevention, and management and health care.According to the WHO criteria there are three steps for screening of NCDs. Step 1: Estimation population need through assessing the current risk profile and advocate for action. Step 2: Formulate and adopt NCD policy. Step 3: Identify policy implementation steps. Management of NCDs should be to increased awareness among the public regarding the signs and symptoms of the disease and its complications.Health promotion strategies, with a strong focus on disease prevention, are needed to empower people to act both individually and collectively to prevent risky behavior, and to create economic, political and environmental conditions that prevent NCDs and their risks. Risk trends need to be monitored and intervention strategies need to be evaluated with respect to their expected outcomes. Issues such as rapid population ageing, gender and income inequality, persistent poverty and the needs of developing countries require close consideration as they influence the prevalence of NCDs – and the success of interventions.
    Diabetes and Metabolic Syndrome Clinical Research and Reviews 01/2010; 4(1):41-47. DOI:10.1016/j.dsx.2008.04.005
  • Samsad Jahan · Rahelee Zinnat · Zahid Hassan · Kazal Boron Biswas · Samira Humaira Habib
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate gender differences, if any, in leptin concentrations from umbilical cord blood of new born infants of mothers with type 2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and Non diabetic (ND) at delivery. Serum leptin concentrations were measured in 105 newborns (53 males and 52 females in the three groups). Blood was taken from the umbilical cord of the babies at delivery. Maternal anthropometric measurements were recorded within 48 hours after delivery. Pearson correlation coefficient was used to explore the relationship between serum leptin concentrations and anthropometric measures of the fetus and their mother. Both Serum leptin level and serum C-peptide was measured by chemiluminescence based ELISA. The median range of leptin concentration in cord blood was ND group: Male [13.91 (3.22 - 47.63)], Female [16.88 (2 - 43.65)]; GDM group: Male [32 (7 - 76.00)], Female [36.73 (4.80 - 81.20)]; DM group: Male [20.90 (2 -76.00)], Female [32 {2.58 - 80.67)]. Cord serum leptin levels correlated with birth weight(r=0.587, p=0.0001), ponderal index (PI) (r=.319, p=0.024)of the babies and body mass index (BMI) (r=-0.299, p=0.035) of their mothers but did not correlate with gestational age, cord serum C-peptide concentration or placental weight at delivery. Leptin concentrations were higher in the female fetus in comparison to the male fetus. Birth weight of the female fetuses were also higher than that of male fetus. We found that there are very strong associations between cord leptin concentrations at delivery and birth weight, ponderal index of the baby, body mass index of the mothers with Type 2 DM. We also found that high leptin levels could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation or adipose tissue is the major determinant of circulating leptin levels.
    10/2009; 29(4):155-8. DOI:10.4103/0973-3930.57346
  • Samira Humaira Habib · Kazal Boron Biswas · Salima Akter · Soma Saha · Liaquat Ali
    [Show abstract] [Hide abstract]
    ABSTRACT: The economic burden resulting from diabetic foot consumes a major portion of resources. The study was undertaken to assess the cost-effectiveness of medical intervention in patients with diabetic foot. At baseline 906 patients were analyzed. Then 200 patients with diabetic foot were purposively selected from a tertiary diabetes care hospital. Of these, 100 were late in detection and poorly managed (late diabetic foot or LDF) and 100 were detected early and properly managed (early diabetic foot or EDF). Among 906 patients, 2.8% (25 patients) were found to develop diabetic foot. Total cost of treatment was US$13,308.16 with an average of US$443.60 per patient. Comparing the cost of patients who underwent amputation with the patients who are not yet amputated, cost difference was US$6657.74. The result showed that cost of amputation was 5.54 times higher than the usual treatment. The average cost of care was US$134 per patient. Among the average annual cost, LDF consumed US$18,918. Fifty percent of the costs were attributable to drugs for both groups of which 77% was for LDF and 29% to hospitalizations. The regression equation showed that medical cost is significantly related to complications. Proper management can substantially reduce the cost of care of patients with diabetic foot.
    Journal of diabetes and its complications 03/2009; 24(4):259-64. DOI:10.1016/j.jdiacomp.2008.12.005 · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and aims Hypertension in people with type 2 diabetes is associated with an increased risk of micro- and macrovascular complications. The hypertension in diabetes studies so far reported, provide both the clinical information on micro- and macrovascular complications, and the information on use of resources associated with treatment and managing complications, thereby allowing the cost-effectiveness of tight blood pressure control in patients with type 2 diabetes to be assessed. The present study was done to assess the cost-effectiveness of tight control of blood pressure in hypertensive diabetic patients, and to calculate the costing, cost analysis and assess the cost-effectiveness of the intended intervention. Incremental cost-effectiveness analysis and incremental cost per event-free year gained within the trial period of these patients was another objective. Materials and methods A total of 200 hypertensive patients with type 2 diabetes undergoing treatment at the Cardiology OPD, BIRDEM and NHN were selected purposively in this cross-sectional study and were interviewed in March 2004 with a preset questionnaire along with scrutinization of guide book records regarding the direct cost (cost of medical advice, investigations, medical and other treatment) and indirect cost (travel cost, cost of productivity loss and accompanying person(s)). Of them 100 were hypertensive patients with type 2 diabetes having uncontrolled blood pressure and ill-managed (BP > 120/80 mmHg) and 100 were hypertensive patients with type 2 diabetes having controlled blood pressure and well-managed (BP ≤ 120/80 mmHg). A comparison was made between these two groups. The degree and extent of complications, treatment outcome, clinical effectiveness, functional level, consumer's out of pocket expense and indirect cost of consumers were calculated. Incremental cost-effectiveness analysis has been calculated for patients (mean age 52 years) with type 2 diabetes. The incremental cost per event-free year gained within the trial period was also calculated. Results Cost analysis in 200 patients showed that the total cost of treatment was US$ 26616.32 (direct cost US$ 17593.12 and indirect cost US$ 9023.2) with an average of US$ 443.60 per patient. On comparing the two groups, the cost of uncontrolled group was found to be higher by US$ 6657.74 than that of controlled group. The incremental cost of intensive management (well-managed group) was US$178 (US$95–US$232) per patient and event-free time gained in the intensive group was 0.55 (0.18–0.92) years and the lifetime gain was 1.19 (0.79–1.81) years. The incremental cost per event-free year gained was US$356 (costs and effects discounted at 6% a year) and US$198 (costs discounted at 6% a year and effects not discounted). Conclusion Intensive blood pressure control in hypertensive patients with type 2 diabetes significantly increased treatment costs but substantially reduced the cost of complications and increased the event-free days. Timely management of patients with diabetic hypertension is both clinically beneficial and cost-effective. It can increase the interval without complications, and the cost-effectiveness ratio compares favorably with many accepted healthcare program. This indicates that comprehensive care can reduce the burden of cardiac events of diabetic patients even in a developing country.
    Diabetes and Metabolic Syndrome Clinical Research and Reviews 09/2008; 2(3):163-170. DOI:10.1016/j.dsx.2008.04.008